***Meta-Analysis
Manuscript Title***

First Name(s) Surnamea, First Name(s) Surnamea, First Name(s) Surnameb, First Name(s) Surnamec, First Name(s) Surnamea

a Department, Institute/University/Hospital, City, (State,) Country

b Department, Institute/University/Hospital, City, (State,) Country

c Department, Institute/University/Hospital, City, (State,) Country

Short Title: to be used as running head

Corresponding Author:

Full name

Department

Institute/University/Hospital

Street Name & Number

City, State, Postal code, Country

Tel:

E-mail:

Number of Tables: Please indicate the number of tables submitted.

Number of Figures: Please indicate the number of figures submitted.

Word count: Please indicate the word count including Abstract and body text. This is not to include the title page, reference list or figure legends.

Keywords: Please provide 3–5 keywords highlighting the most important points of your paper.

**Abstract**

A short Abstract should summarize the main points and reflect the content of the article. It should be written in a clear and concise way and be structured using the following subheadings: Background, Objectives, Method, Results, and Conclusions. Abbreviations used in the main text may be introduced and used. Use neither bibliographic references nor references to figures or tables in the Abstract.

Please refer to the Author Guidelines for more information about the maximum accepted word count of the Abstract in your chosen journal. Where no specific word count is provided, an abstract of between 200-400 words is permitted.
**Introduction**

The Introduction should provide a summary of the background to the relevant field of research and the specific problems addressed and should state the hypotheses being explored as well as the main goal(s) of the study. Conclusions or findings should not appear in the Introduction.

**Methods**

The Methods section should clearly list all inclusion and exclusion criteria, methods of research, and variables evaluated and should state how outcomes were assessed. All terms should be adequately defined and statistical information should be sufficiently detailed. Please indicate if a review protocol exists, if and where it can be accessed, and, if available, provide registration information including the registration number. We strongly encourage authors to comply with the [Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.](http://www.prisma-statement.org/)

**Results**

The Results section should describe the most important findings of the analysis. The results of the meta-analysis should be presented, including confidence intervals and measures of consistency. The most important results should be indicated, and relevant trends and patterns should be described.

**Discussion/Conclusion**

The Discussion/Conclusion should provide an evaluation of the results. There should be a clear discussion of the implications, significance, and novelty of the results presented and whether the data support or contradict previous studies.

**Statements**

All papers must contain the following statements after the main body of the text and before the reference list:

**A****cknowledgement (optional)**

In the Acknowledgement section, authors must include individuals and organizations that have made substantive contributions to the research or the manuscript. An exception is where funding was provided, which should be included in Funding Sources. Please refer to the Guidelines issued by the [ICMJE](http://www.icmje.org/) to determine non-author contributors that should be included in the Acknowledgement section.

**Statement of Ethics**Published research must comply with the guidelines for human studies and should include evidence that the research was conducted ethically in accordance with the [World Medical Association Declaration of Helsinki](https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.wma.net%2Fpolicies-post%2Fwma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects%2F&data=04%7C01%7Ck.fava%40karger.com%7Cff60788f01494d8ede1508d90a2bbe0c%7C69e7eb606e904a0590b15b8d6d697087%7C0%7C0%7C637552005543124152%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=W1QXYwb9rSAsUtYOPMhRcBNr%2Bxd92FHLjnwUduQCGp8%3D&reserved=0).If the study is based exclusively on published literature, please declare this in the Statement of Ethics. An example statement can be found here: *“An ethics statement is not applicable because this study is based exclusively on published literature.”*

If the study includes data obtained from sources other than published articles, please address the following aspects in your Statement of Ethics.

Study approval statement: Provide name and affiliation of the committee who approved the study and the decision reference number. An example statement can be found here: "*This study protocol was reviewed and approved by [committee name and affiliation], approval number [XXX]*." If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be stated, including the name of the ethics committee who made that decision.

Consent to participate statement: For studies using human participants, state whether written informed consent was obtained from participants (or their parent/legal guardian/next of kin) to participate in the study. If written informed consent was not required, or if the study has been granted an exemption from requiring written informed consent, this should also be stated, including the name of the ethics committee who made that decision.

###### Consent to publish statement (if applicable): If your research includes novel case report data, state whether written informed consent was obtained from participants (or their parents/legal guardians/next-of-kin) for publication of the details of their medical case and any accompanying images. Information revealing the subject’s identity is to be avoided. All patients should be identified by numbers or aliases and not by their real names.

###### Conflict of Interest Statement

Authors are required to disclose any possible conflicts of interest. All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Also the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. If there is no conflict of interest, please state: “The authors have no conflicts of interest to declare.”

###### Funding Sources

Authors must give full details about the funding of any research relevant to their study, including sponsor names and explanations of the roles of these sources in the preparation of data or the manuscript.

###### Author Contributions

In the Author Contributions section, a short statement detailing the contributions of each person named as an author should be included. Contributors to the paper who do not fulfil the [ICMJE Criteria for Authorship](https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.icmje.org%2Frecommendations%2Fbrowse%2Froles-and-responsibilities%2Fdefining-the-role-of-authors-and-contributors.html&data=04%7C01%7Ck.fava%40karger.com%7Cff60788f01494d8ede1508d90a2bbe0c%7C69e7eb606e904a0590b15b8d6d697087%7C0%7C0%7C637552005543144066%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=QBfoT6JcFIpswsIllt2YnvL4fkIMHENDcVTlHkfgnPI%3D&reserved=0) should be credited in the Acknowledgement section.

If an author is removed from or added to the listed authors after submission, an explanation and a signed statement of agreement confirming the requested change are required from all the initially listed authors and from the author to be removed or added.

**Data Availability Statement**

Authors are required to provide a Data Availability Statement in their article that details whether data are available and where they can be found. The journal’s data sharing policy strongly encourages authors to make all datasets on which the conclusions of the paper rely available to editors, reviewers and readers without unnecessary restriction wherever possible. In cases where research data are not publicly available on legal or ethical grounds, this should be clearly stated in the Data Availability Statement along with any conditions for accessing the data. Examples of Data Availability Statements and additional information on the data sharing policy can be found on the journal homepage under “Guidelines”.

**References [Numerical]**

References in the text should be identified using Arabic numerals [in square brackets].

References should be listed using the Vancouver style. The reference list should include only those publications which are cited in the text, arranged numerically in the order in which they are cited. Please number the reference list as shown below (i.e., without using full stops, brackets, etc.). The authors’ surnames should be followed by their initials with no punctuation other than a comma to separate individual authors. A maximum of 6 authors should be listed (followed by “et al.” if there are more than 6 authors). Material submitted for publication but not yet accepted should be referred to as “unpublished data” and should not be included in the reference list. More information on good referencing practice, as well as further examples, can be found in [The National Library of Medicine Style Guide for Authors](https://www.ncbi.nlm.nih.gov/books/NBK7256/).

Examples

Papers published in journals:

1 Sawant KV, Xu R, Cox R, Hawkins H, Sbrana E, Kolli D, et al. Chemokine CXCL1-mediated neutrophil trafficking in the lung: role of CXCR2 activation. J Innate Immun. 2015 Jul;6(7):647–58.

(Journal names should be abbreviated according to the Index Medicus.)

Papers published only with DOI number:

2 Chen C, Hu Z. ApoE polymorphisms and the risk of different subtypes of stroke in the Chinese population: a comprehensive meta-analysis. Cerebrovasc Dis. DOI: 10.1159/000442678.

Monographs:

3 Matthews DE, Farewell VT. Using and understanding medical statistics. 5th ed, revised. Basel: Karger; 2015.

Edited Books:

4 Cohen SR, Gardner TW. Diabetic retinopathy and diabetic macular edema. In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, Do DV, editors. Retinal pharmacotherapeutics. Dev Ophthalmol. Basel: Karger; 2016. Vol. 55; p. 137–46.

Websites:

5 Karger Publishers [Internet]. Basel: Transforming Vesalius: The 16th-Century Scientific Revolution Brought to Life for the 21st Century [cited 2013 Feb 4]. Available from: <http://www.vesaliusfabrica.com/en/new-fabrica.html>.

**Figure Legends**

Fig. 1. Legend text.

Fig. 2. Legend text.

Figures should be mentioned in the manuscript text as follows:
Without round brackets:

“…shown in Figure 1…” or “…shown in Figures 1 and 4…” or “…shown in Figures 2–6…” always with capital letters and written out.

With round brackets:

“(shown in Fig. 1)” or “(shown in Fig. 1, 4)” or “(shown in Fig. 2–6)”, always abbreviated as “Fig.” followed by the number or numbers after a full stop and a space.

In the Legend:

“Fig. 1.” or “Fig. 1. a”, always abbreviated as “Fig.” followed by the number after a full stop and a space

Please note that the actual figures and all tables should be uploaded as separate items in their original file format.